Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
| Autor: | Lee, Jung-Min, Nair, Jayakumar, Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M, Merino, Maria J, Swisher, Elizabeth M, Harrell, Maria I, Trepel, Jane B, Lee, Min-Jung, Bagheri, Mohammad H, Botesteanu, Dana-Adriana, Steinberg, Seth M, Minasian, Lori, Ekwede, Irene, Kohn, Elise C |
|---|---|
| Zdroj: | In The Lancet Oncology February 2018 19(2):207-215 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|